{"id":80574,"date":"2026-05-12T13:09:11","date_gmt":"2026-05-12T13:09:11","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/80574\/"},"modified":"2026-05-12T13:09:11","modified_gmt":"2026-05-12T13:09:11","slug":"hims-hers-plummets-15-after-first-quarter-loss-weak-guidance","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/80574\/","title":{"rendered":"Hims & Hers plummets 15% after first-quarter loss, weak guidance"},"content":{"rendered":"

Piotr Swat | Lightrocket | Getty Images<\/p>\n

Telehealth company Hims & Hers’<\/a> stock plummeted in early trading Tuesday after posting a first-quarter loss and weak earnings guidance for the year ahead. <\/p>\n

The digital health firm reported a net loss of $92 million in its first quarter earnings<\/a> on Monday, compared with roughly $50 million for the same period the prior year. Its adjusted Ebitda was $44 million, down from $91 million last year. Meanwhile, revenue was up 4% to $608 million. Average monthly revenue per subscriber was $80, down from $85 last year. <\/p>\n

Hims is expecting revenue in a range between $680 million and $700 million for the second quarter, and is forecasting up to $3 billion in revenue for the full year.<\/p>\n

It forecast adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) up to $55 million for the second quarter, and up to $350 million for the full year. <\/p>\n

The company’s stock was last seen down 15.5% in premarket trading.<\/p>\n

Stock Chart IconStock chart icon\"hide<\/p>\n

Hims & Hers shares year to date.<\/p>\n

Citi analysts described the forecast as “mixed” and noted that Hims & Hers second-quarter outlook came in below Citi’s estimates.<\/p>\n

The analysts also flagged that the first quarter marks a “transition” phase for the company as it reduces its reliance on compounded GLP-1s.<\/p>\n

Selling branded GLP-1 weight loss drugs<\/p>\n

Hims reached a deal with Novo Nordisk<\/a> in March to sell its GLP-1 weight loss drug Wegovy<\/a> on its platform while committing to stop advertising cheaper copycat versions of the drug known as compounding drugs.<\/p>\n

Novo said in February that it would sue Hims for selling copycat versions of the Wegovy pill for $49, $100 less than what Novo sells it for.<\/p>\n

“The action by Hims & Hers is illegal mass compounding that poses a significant risk to patient safety,”\u00a0Novo said in a statement<\/a> at the time. Hims pulled the pill shortly after the backlash received. <\/p>\n

Hims stock has often reacted strongly to any news that may affect its ability to sell weight loss drugs to consumers, which has been highly profitable for the telehealth company.<\/p>\n

The firm has faced controversy over its selling of copycat weight loss drugs via a regulatory loophole that enables companies other than the patent holder to sell a drug if it’s in shortage. Although the shortage was resolved, Hims continued selling its version of the drugs, despite it being patented until 2032.<\/p>\n

Novo even partnered with Hims last year to offer discounted treatments, but the deal ended quickly, with Novo accusing Hims of deceptive marketing and raising concerns about patient safety.<\/p>\n

“It’s a very different situation than the last time we did this,” Novo CEO Mike Doustdar told CNBC\u00a0in March. “Hims & Hers have agreed that upon receiving our products, they will no longer advertise, promote, market compounded products to the masses.”<\/p>\n

\u2014 Elsa Ohlen contributed to this report<\/p>\n

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Piotr Swat | Lightrocket | Getty Images Telehealth company Hims & Hers’ stock plummeted in early trading Tuesday…\n","protected":false},"author":2,"featured_media":80575,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[1328,438,1275,700,1274,42886,286,272,1273,280,277],"class_list":{"0":"post-80574","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-breaking-news-markets","9":"tag-business","10":"tag-business-news","11":"tag-health-care-industry","12":"tag-hims-hers-health-inc","13":"tag-intl-premarket-movers","14":"tag-markets","15":"tag-novo-nordisk","16":"tag-novo-nordisk-a-s","17":"tag-weight-loss","18":"tag-weight-loss-drugs"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116561770482734026","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/80574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=80574"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/80574\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/80575"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=80574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=80574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=80574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}